Philip Morris Int'l cuts earnings forecast

Associated Press |

NEW YORK (AP) — Philip Morris International Inc., the seller of Marlboro cigarettes overseas, cut its full-year earnings forecast Thursday as it deals with currency fluctuations, economic difficulties in the European Union and Asia and some discounted prices in Australia.

The company, based in New York and Lausanne, Switzerland, now foresees full-year earnings between $4.87 and $4.97 per share. Its previous forecast was for $5.09 to $5.19 per share.

Analysts surveyed by FactSet anticipate earnings of $5.18 per share.



CEO André Calantzopoulos said in a statement that if Philip Morris International continues to see price discounting at the low end of the Australian market, it may have to reduce the lower end of its outlook for 2014 adjusted earnings per share growth of 6 percent to 8 percent.

Philip Morris International is also planning to end cigarette production at its plant in Bergen op Zoom, Netherlands, by Sept. 1. The company said the factory closing will likely result in a pretax charge of about 24 cents per share. It expects the majority of the charge to be recorded in the second quarter.

The cigarette marker is also stopping cigarette production in Australia by year's end, which is expected to result in a charge of a penny per share in the first quarter.

In addition, the company announced it purchased U.K.-based e-cigarette maker Nicocigs Ltd. Financial terms were not disclosed. The company said that the deal won't materially affect its 2014 financial position.

Shares of Philip Morris International fell $1.09 to $87.80 in premarket trading.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
TOSCF Tosoh Corp 8.80 0.00 0.00 0

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

WayBetter

The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…

CF0005, LLC dba Mesa-Marshall #1-2

MESA Resources, Inc. ("MESA") is sponsoring the development of the oil & gas well completion project "Mesa-Marshall #1-2". MESA, founded in 1992, is engaged in the acquisition, exploration and development…